The epidemic of type 2 diabetes and impaired glucose tolerance is one of the main causes of morbidity and mortality worldwide. In both disorders, tissues such as muscle, fat and liver become less responsive or resistant to insulin. This state is also linked to other common health problems, such as obesity, polycystic ovarian disease, hyperlipidaemia, hypertension and atherosclerosis. The pathophysiology of insulin resistance involves a complex network of signalling pathways, activated by the insulin receptor, which regulates intermediary metabolism and its organization in cells. But recent studies have shown that numerous other hormones and signalling events attenuate insulin action, and are important in type 2 diabetes.
D
espite periods of feeding and fasting, plasma glucose remains in a narrow range between 4 and 7 mM in normal individuals. This tight control is governed by the balance between glucose absorption from the intestine, production by the liver and uptake and metabolism by peripheral tissues. Insulin increases glucose uptake in muscle and fat (see Box 1) , and inhibits hepatic glucose production, thus serving as the primary regulator of blood glucose concentration. Insulin also stimulates cell growth and differentiation, and promotes the storage of substrates in fat, liver and muscle by stimulating lipogenesis, glycogen and protein synthesis, and inhibiting lipolysis, glycogenolysis and protein breakdown (Fig. 1) . Insulin resistance or deficiency results in profound dysregulation of these processes, and produces elevations in fasting and postprandial glucose and lipid levels.
Insulin increases glucose uptake in cells by stimulating the translocation of the glucose transporter GLUT4 from intracellular sites to the cell surface (see Box 1) . Up to 75% of insulin-dependent glucose disposal occurs in skeletal muscle, whereas adipose tissue accounts for only a small fraction 1 . Despite this, mice with a knockout of the insulin receptor in muscle have normal glucose tolerance 2 , whereas those with a knockout of the insulin-sensitive glucose transporter in fat have impaired glucose tolerance, apparently owing to insulin resistance being induced in muscle and liver 3 . Both obesity and lipoatrophy also cause insulin resistance and predisposition to type 2 diabetes, demonstrating that adipose tissue is crucial in regulating metabolism beyond its ability to take up glucose 4 . Although insulin does not stimulate glucose uptake in liver, it blocks glycogenolysis and gluconeogenesis, and stimulates glycogen synthesis, thus regulating fasting glucose levels. Insulin action in tissues not normally considered insulin sensitive, including brain and pancreatic ȋ-cell, may also be important in glucose homeostasis 2, 5 (see below).
Proximal insulin-signalling pathways
The insulin receptor
The insulin receptor belongs to a subfamily of receptor tyrosine kinases that includes the insulin-like growth factor (IGF)-I receptor and the insulin receptor-related receptor (IRR) 6 . These receptors are tetrameric proteins consisting of two Ȋ-and two ȋ-subunits that function as allosteric enzymes in which the Ȋ-subunit inhibits the tyrosine kinase activity of the ȋ-subunit. Insulin binding to the Ȋ-subunit leads to derepression of the kinase activity in the ȋ-subunit followed by transphosphorylation of the ȋ-subunits and a conformational change that further increases kinase activity 6 . Insulin, IGF-I and the IRR receptors can form functional hybrids; thus, an inhibitory mutation in one receptor can inhibit the activity of the others 7 . Homologues of the insulin/IGF-I receptor have been identified in Drosophila, Caenorhabditis elegans and metazoan marine sponges 8 . These lower organisms use some of the same downstream signals critical to the regulation of mammalian cells, including phosphatidylinositol-3-OH kinase (PI(3)K), Akt and forkhead transcription factors. Inhibitory mutants of the insulin/IGF system in C. elegans live longer than normal animals, raising a number of interesting questions about the association of hyperinsulinaemia/insulin resistance with conditions that shorten life span, such as obesity, diabetes and accelerated atherosclerosis.
Insulin-receptor substrates
At least nine intracellular substrates of the insulin/IGF-I receptor kinases have been identified (Fig. 2) . Four of these belong to the family of insulin-receptor substrate (IRS) proteins 9 . Other substrates include Gab-1, p60 dok , Cbl, APS and isoforms of Shc 10 . The phosphorylated tyrosines in these substrates act as 'docking sites' for proteins that contain SH2 (Src-homology-2) domains. Many of these SH2 proteins are adaptor molecules, such as the p85 regulatory subunit of PI(3)K and Grb2, or CrkII, which activate small G proteins by binding to nucleotide exchange factors. Others are themselves enzymes, including the phosphotyrosine phosphatase SHP2 and the cytoplasmic tyrosine kinase Fyn. Substrate binding to these SH2 proteins can regulate their activities, or in some cases their subcellular location.
Although the IRS proteins are highly homologous, recent studies in knockout mice and cell lines suggest that they serve complementary, rather than redundant, roles in insulin/IGF-I signalling. IRS-1-knockout mice exhibit generalized pre-and post-natal growth retardation, as well as insulin resistance in peripheral tissues and impaired glucose tolerance 11, 12 . IRS-2-knockout mice also exhibit insulin resistance in both peripheral tissues and liver, but have defective growth in only some tissues, including certain regions of the brain, islets and retina 13, 14 . In the IRS-2 -/-mouse, this multifactorial insulin resistance combined with decreased ȋ-cell mass leads to development of type 2 diabetes 14 . By contrast, IRS-3-and IRS-4-knockout mice have normal or near normal growth and metabolism 15 . The different IRS proteins seem to serve different functions at the cellular level, probably owing to differences in tissue distribution, subcellular localization and intrinsic activity of the proteins. IRS-1-knockout cells exhibit reduced IGF-I-stimulated DNA synthesis 11, 12 and fail to differentiate into adipocytes in culture 16 . Likewise, the mitogenic response mediated by IRS-2 is weaker than that by produced by IRS-1 (ref. 17 ). IRS-2-knockout cells show a major defect in insulin-stimulated glucose transport 14 . The roles of IRS-3 and 4 are less clear in cultured cells, but some data suggest that these substrates may act as negative regulators of IRS-1 and -2 (ref. 18 ).
Inhibition of insulin-receptor signalling
In addition to tyrosine phosphorylation, both the insulin receptor and IRS proteins undergo serine phosphorylation, which may attenuate signalling by decreasing insulin-stimulated tyrosine phosphorylation 19 and promote interaction with 14-3-3 proteins 20 . These inhibitory phosphorylations provide negative feedback to insulin signalling and serve as a mechanism for cross-talk from other pathways that produce insulin resistance. Several kinases have been implicated in this process, including PI(3)K, Akt, glycogen synthase kinase (GSK)-3 and mammalian target of rapamycin (mTOR). Recent data indicate that obesity-induced attenuation of insulin signalling might arise from the sequential activation of protein kinase C (PKC) and inhibitor of nuclear factor-ȔB (IȔB) kinase, although the details of this pathway have not been elucidated 21, 22 . Insulin action is also attenuated by protein tyrosine phosphatases (PTPases), which catalyse the rapid dephosphorylation of the receptor and its substrates. A number of PTPases have been identified that catalyse dephosphorylation of the insulin receptor in vitro, some of which are expressed in insulin-responsive cells, or upregulated in states of insulin resistance. Most attention has focused on the cytoplasmic phosphatase PTP1B. Knockout of PTP1B leads to increased tyrosine phosphorylation of the insulin receptor and IRS proteins in muscle and improved insulin sensitivity 23 . PTP1B -/-mice are also resistant to diet-induced obesity, suggesting the brain as an important site of action. This combination of effects implicates PTP1B as a potential therapeutic target in diabetes and obesity.
PI(3)K and insulin action
PI(3)K has a pivotal role in the metabolic and mitogenic actions of insulin and IGF-I (ref. 24) . Inhibitors of class Ia PI(3)K, or transfections with dominant negative constructs of the enzyme, block most metabolic actions of insulin, including stimulation of glucose transport, glycogen and lipid synthesis. PI(3)K consists of a p110 catalytic subunit and a p85 regulatory subunit that possesses two SH2 domains that interact with tyrosine-phosphorylated pYMXM and pYXXM motifs in IRS proteins 25 . At least eight isoforms of the regulatory subunits have been identified. These are derived from three genes (p85Ȋ, p85ȋ and P55 PIK ) 26 and alternative splicing of p85Ȋ to produce AS53/p55Ȋ 27 and p50Ȋ 28 . Of these, p85Ȋ is predominant and thought to be the main response pathway for most stimuli.
The exact roles of the different regulatory subunits of PI(3)K in insulin action are unclear. Splice variants possess differences in potencies for enzyme activation 27 , tissue distribution 27,28 and sensitivity to insulin 29 . Knockout mice with a disruption of all three isoforms derived from the p85Ȋ gene die shortly after birth 30 , whereas heterozygous knockout mice or mice lacking only full-length p85Ȋ are viable and exhibit improved insulin sensitivity (ref. 31 , and F. Mauvais-Jarvis et al., personal communication). Cell lines derived from heterozygous knockouts also exhibit increased insulin/IGF-I signalling, which seem to be due to improved stoichiometry of the interaction (see below).
The activation of PI(3)K may transmit multiple signals. PI(3)K catalyses the phosphorylation of phosphoinositides on the 3-position to produce phosphatidylinositol-3-phosphates, especially PtdIns(3,4,5)P 3 , which bind to the pleckstrin homology (PH) domains of a variety of signalling molecules thereby altering their activity or subcellular localization 32 . Moreover, PI(3)K also possesses serine kinase activity, and both the regulatory and catalytic subunits of the enzyme can interact with other signalling proteins. Indeed, recent studies suggest that these proteins may be important in insulin action independent of PtdIns(3,4,5)P 3 generation Insulin increases glucose transport in fat and muscle cells by stimulating the translocation of the transporter GLUT4 from intracellular sites to the plasma membrane (see figure below). GLUT4 is found in vesicles that continuously cycle from intracellular stores to the plasma membrane. Insulin increases glucose transport by increasing the rate of GLUT4-vesicle exocytosis, and by slightly decreasing the rate of internalization 99 . Although the exact mechanisms are unknown, it is likely that the insulin-responsive GLUT4 vesicle is tethered to intracellular sites, perhaps defined by a microtubule network 100 . Phosphorylation events probably catalysed by PtdIns(3,4,5)P 3 -dependent kinases release vesicles from these sites, allowing trafficking of GLUT4 to the cell surface. Recent evidence suggests that these vesicles move along microtubule tracks en route to the cell surface, perhaps via kinesin motors. The vesicles then dock and fuse with the plasma membrane, allowing the extracellular exposure of the GLUT4 protein.
It is likely that the actin cytoskeleton is also crucial in insulinstimulated GLUT4 translocation. Insulin causes remodelling of cortical actin filaments just below the plasma membrane, and induces membrane ruffling. This effect probably reflects actin polymerization and depolymerization involving lamelipodia and/or filopodia formation. The actin depolymerizing agent cytochalasin D, as well as the actin monomer-binding toxins latrunculin A and B, partially inhibit the effects of insulin on actin and GLUT4 translocation.
The docking and fusion of the GLUT4 vesicle at the plasma membrane may also be subject to regulation by insulin. The v-SNARE protein VAMP2 physically interacts with its t-SNARE counterpart syntaxin 4 on GLUT4 vesicles during vesicle docking and fusion with the plasma membrane 99 . Although these SNARE interactions are essential, neither SNARE protein seems to be a direct target of insulin. Instead, the SNARE accessory proteins Synip and Munc18c may be involved in the control of GLUT4 docking and fusion in an insulin-dependent, PI(3)K-independent manner.
Phosphotidylinositol-3-phosphates regulate three main classes of signalling molecules: the AGC family of serine/threonine protein kinases 34 , guanine nucleotide-exchange proteins of the Rho family of GTPases 35 , and the TEC family of tyrosine kinases 36 . PI(3)K also activates the mTOR/FRAP pathway, and might be involved in regulation of phospholipase D, leading to hydrolysis of phosphatidylcholine and increases in phosphatidic acid and diacylglycerol. The best characterized of the AGC kinases is phosphoinositide-dependent kinase 1 (PDK1), one of the serine kinases that phosphorylates and activates the serine/threonine kinase Akt/PKB 37 . Akt possesses a PH domain that also interacts directly with PtdIns(3,4,5)P 3 , promoting membrane targeting of the protein and catalytic activation. Akt has been suggested to be important in transmission of the insulin signal, by phosphorylation of the enzyme GSK-3 (see below), the forkhead transcription factors and cAMP response element-binding protein 38, 39 . Although studies using inhibitory or activated forms of Akt have not uniformly inhibited or mimicked insulin actions 40 , deletion of Akt2 produces hepatic insulin resistance in mice 41 . Other AGC kinases that are downstream of PI(3)K include serum-and glucocorticoid-regulated kinase and the atypical PKCs, PKC-Ȑ and -ȕ 42 . Akt and/or the atypical PKCs seem to be required for insulinstimulated glucose transport.
Activity of this pathway is also determined by phosphatidylinositol-3-phosphates such as phosphatase and tensin homologue 43 and the SH2 domain-containing inositol-5-phosphatase SHIP2 (ref. 44 ). Overexpression of these enzymes leads to decreased levels of PtdIns(3,4,5)P 3 . This might terminate signal transduction and/or change the nature of the phosphoinositides, altering the binding specificity to PH or phox homology domains. Disruption of these genes or reducing expression of these messenger RNAs yields mice with increased insulin sensitivity 45 .
The CAP/Cbl pathway and lipid rafts
In addition to PI(3)K activity, other signals seem to be required for insulin-stimulated glucose uptake 10 . This second pathway appears to involve tyrosine phosphorylation of the Cbl protooncogene 46 most insulin-responsive cells, Cbl is associated with the adapter protein CAP, which binds to proline-rich sequences in Cbl through its carboxyl-terminal SH3 domain 47 . CAP is expressed in insulin-sensitive tissues, is markedly induced during adipocyte differentiation and its expression is increased by insulin-sensitizing peroxisome proliferator-activated receptor-ȍ (PPARȍ) agonists 48 . CAP belongs to a family of adapter proteins with a common organization containing three SH3 domains and a region of similarity to the peptide sorbin, referred to as a sorbin homology (SoHo) domain 49 . Upon phosphorylation, the Cbl-CAP complex translocates to lipid raft domains in the plasma membrane, mediated by the interaction of the SoHo domain of CAP with the protein flotillin 50 . Expression of dominant-interfering CAP mutants that cannot bind to Cbl or flotillin inhibit Cbl translocation and insulinstimulated glucose uptake. Translocation of phosphorylated Cbl recruits the adapter protein CrkII to the lipid raft via interaction of the SH2 domain of CrkII with phospho-Cbl 51 . CrkII also forms a constitutive complex with the guanyl nucleotide-exchange protein C3G. Once translocated into lipid rafts, C3G comes into proximity with the G protein TC10, and catalyses the exchange of GTP for GDP, resulting in the activation of the protein 51 . The localization of TC10 in rafts is required for its activation by insulin 52 . Once activated, TC10 seems to provide a second signal to the GLUT4 protein that functions in parallel with the activation of the PI(3)K pathway 51 . This may involve the stabilization of cortical actin, which seems to be important in GLUT4 vesicle translocation to the plasma membrane (see Box 1).
Insulin-stimulated phosphorylation cascades
As is the case for other growth factors, insulin stimulates the mitogen-activated protein (MAP) kinase extracellular signalregulated kinase (ERK) (Fig. 2) . This pathway involves the tyrosine phosphorylation of IRS proteins and/or Shc, which in turn interact with the adapter protein Grb2, recruiting the Son-of-sevenless (SOS) exchange protein to the plasma membrane for activation of Ras. The activation of Ras also requires stimulation of the tyrosine phosphatase SHP2, through its interaction with receptor substrates such as Gab-1 or IRS1/2. Once activated, Ras operates as a molecular switch, stimulating a serine kinase cascade through the stepwise activation of Raf, MEK and ERK. Activated ERK can translocate into the nucleus, where it catalyses the phosphorylation of transcription factors such as p62 TCF , initiating a transcriptional programme that leads to cellular proliferation or differentiation 53 . Blockade of the pathway with dominant negative mutants or pharmacological inhibitors prevents the stimulation of cell growth by insulin, but has no effect on the metabolic actions of the hormone 54 . Insulin increases synthesis and blocks the degradation of proteins through activation of mTOR. mTOR is a member of the PI(3)K family of proteins, but seems to act primarily as a serine, rather than lipid kinase 55 . The stimulation of this protein kinase involves PI(3)K activation, although another signal may also be required 56 . mTOR can control the mammalian translation machinery by direct phosphorylation and activation of p70 ribosomal S6 kinase (p70 rsk ) 57 , as well as phosphorylation of the initiation factor 4E for eukaryotic translation (eIF-4E) inhibitor, PHAS1 or 4E-binding protein 1 (ref. 58). P70 rsk activates ribosome biosynthesis by phosphorylating the ribosomal S6 protein, producing increased translation of mRNAs with a 5፱-terminal oligopyrimidine tract. P70 rsk also requires a second PtdIns(3,4,5)P 3 -dependent phosphorylation, presumably catalysed by PDK1. Phosphorylation of PHAS-1 by mTOR results in its dissociation from eIF-2, allowing capdependent translation of mRNAs with a highly structured 5፱-untranslated region. Although the mechanism of activation of mTOR remains unclear, it seems to require the presence of amino acids in the media for full activation by growth factors, and thus may also represent a nutrient sensor 55 .
Glucose and lipid regulation Regulation of glycogen synthesis
Insulin stimulates glycogen accumulation through a coordinated increase in glucose transport and glycogen synthesis. The hormone activates glycogen synthase by promoting its dephosphorylation, through the inhibition of kinases such as PKA or GSK-3 (ref. 59) , and activation of protein phosphatase 1 (PP1) 60 . Upon its activation downstream of PI(3)K, Akt phosphorylates and inactivates GSK-3, decreasing the rate of phosphorylation of glycogen synthase, thus increasing its activity state 59 . Figure 3 The regulation of glucose metabolism in the liver. In the hepatocyte, insulin stimulates the utilization and storage of glucose as lipid and glycogen, while repressing glucose synthesis and release. This is accomplished through a coordinated regulation of enzyme synthesis and activity. Insulin stimulates the expression of genes encoding glycolytic and fatty-acid synthetic enzymes (in blue), while inhibiting the expression of those encoding gluconeogenic enzymes (in red). These effects are mediated by a series of transcription factors and co-factors, including sterol regulatory elementbinding protein (SREBP)-1, hepatic nuclear factor (HNF)-4, the forkhead protein family (Fox) and PPARȍ co-activator 1 (PGC1). The hormone also regulates the activities of some enzymes, such as glycogen synthase and citrate lyase (in green), through changes in phosphorylation state. GK, glucokinase; Glucose-6-P, glucose-6-phosphate; G-6-Pase, glucose-6-phosphatase; F-1,6-Pase, fructose-1,6-bisphosphatase; PEPCK, phosphoenolpyruvate carboxykinase; PFK, phosphofructokinase; PK, pyruvate kinase; ACC, acetyl-CoA carboxylase; FAS, fatty-acid synthase. PP1 globally, but rather specifically targets discrete pools of the phosphatase, primarily increasing PP1 activity localized at the glycogen particle. The compartmentalized activation of PP1 by insulin is due to glycogen-targeting subunits, which serve as 'molecular scaffolds' , bringing together the enzyme directly with its substrates glycogen synthase and phosphorylase in a macromolecular complex, and in the process exerting profound effects on PP1 substrate-specific activity 61 . Four different proteins have been reported to target PP1 to the glycogen particle. Despite a proposed common function, no two targeting subunits share more than 50% sequence homology, and this is largely confined to the PP1-and glycogen-binding regions. Overexpression of these scaffolding proteins in cells or in vivo results in a marked increase in cellular glycogen levels 61 . Although the mechanism by which insulin activates glycogen-associated PP1 remains unknown, inhibitors of PI(3)K block this effect, suggesting that PtdIns(3,4,5)P 3 -dependent protein kinases are involved. These scaffolding proteins have a critical permissive role in the hormonal activation of the enzyme, perhaps interacting with additional proteins that regulate the interaction of PP1 with glycogen synthase and phosphorylase.
Regulation of gluconeogenesis
Insulin inhibits the production and release of glucose by the liver by blocking gluconeogenesis and glycogenolysis (Fig. 3) . This occurs through a direct effect of insulin on the liver 62 , as well as by indirect effects of insulin on substrate availability 63 . Insulin can also influence glucose metabolism indirectly by changes in free fatty acids generated from visceral fat, the so called 'single gateway' hypothesis 64 . Because visceral fat is less sensitive to insulin than subcutaneous fat, even after a meal there is little suppression of lipolysis by the hormone in this fat depot. The resulting direct flux of fatty acids derived from these fat cells through the portal vein to the liver can stimulate glucose production, thus providing a signal for both insulin action and insulin resistance in the liver.
Insulin directly controls the activities of a set of metabolic enzymes by phosphorylation or dephosphorylation and also regulates the expression of genes encoding hepatic enzymes of gluconeogenesis and glycolysis 65 . It inhibits the transcription of the gene encoding phosphoenolpyruvate carboxylase, the rate-limiting step in gluconeogenesis 66 . The hormone also decreases transcription of the genes encoding fructose-1,6-bisphosphatase and glucose-6-phosphatase, and increases transcription of glycolytic enzymes such as glucokinase and pyruvate kinase, and lipogenic enzymes such as fatty acid synthase and acetyl-CoA carboxylase. Although the transcription factors that control the expression of these genes have remained elusive, new data suggest a potential role for the forkhead family of transcription factors through phosphorylation by Akt-related protein kinases 39 , and the PPARȍ co-activator PGC-1 (ref. 67 ).
Regulation of lipid synthesis and degradation
As is the case with carbohydrate metabolism, insulin also promotes the synthesis of lipids, and inhibits their degradation. Recent studies suggest that many of these changes require an increase in the transcription factor steroid regulatory element-binding protein (SREBP)-1c 68 . Dominant negative forms of SREBP-1 can block expression of these gluconeogenic and lipogenic genes 69 , whereas overexpression can increase their transcription 68 . Hepatic SREBP levels are increased in some rodent models of lipodystrophy, and this is coordinated with increases in fatty acid synthesis and gluconeogenesis, the exact phenotype observed in genetic models of obesityinduced diabetes 70 . Thus, increased expression of SREBP-1c might contribute to the insulin resistance observed in liver of diabetic rodents, with increased rates of both gluconeogenesis and lipogenesis. The pathways that account for the changes in SREBP-1c expression in response to insulin or other metabolic changes are not known, but probably lie downstream of the IRS/PI(3)K pathway.
In adipocytes, glucose is stored primarily as lipid, owing to increased uptake of glucose and activation of lipid synthetic enzymes, including pyruvate dehydrogenase, fatty acid synthase and acetyl-CoA carboxylase. Insulin also profoundly inhibits lipolysis in adipocytes, primarily through inhibition of the enzyme hormonesensitive lipase 71 . This enzyme is acutely regulated by control of its phosphorylation state, which is activated by PKA-dependent phosphorylation, and inhibited as a result of a combination of kinase inhibition and phosphatase activation. Insulin inhibits the activity of the lipase primarily through reductions in cAMP levels, owing to the activation of a cAMP-specific phosphodiesterase in fat cells 72 .
What causes insulin resistance?
The insulin resistance of obesity and type 2 diabetes is characterized by defects at many levels, with decreases in receptor concentration and kinase activity, the concentration and phosphorylation of IRS-1 and -2, PI(3)K activity, glucose transporter translocation, and the activity of intracellular enzymes 10 . Activation of the MAP kinase pathway by insulin is not reduced in type 2 diabetes, perhaps allowing for some of the detrimental effects of chronic hyperinsulinaemia on cellular growth in the vasculature 73 . Genetic and acquired factors can profoundly influence insulin sensitivity. Genetic defects in the insulin receptor are relatively rare, but represent the most severe forms of insulin resistance, and are exemplified by leprechaunism, the Rabson Mendenhall Syndrome, and the type A syndrome of insulin resistance 74 . Differences in clinical presentation may be due to the severity of the genetic defect, the ability of the mutant receptors to form hybrids with IGF-I or other receptors, and other background genetic or acquired factors that modify the insulin-resistant state. Type 2 diabetes is polygenic and may involve polymorphisms in multiple genes encoding the proteins involved in insulin signalling, insulin secretion and intermediary metabolism 75 . Targeted deletions of the components of insulin signalling in vivo using homologous recombination have yielded some insight into the complexity of these mechanisms. Although some single defects in the insulin-signalling pathway, such as knockout of the insulin receptor IRS-2 or Akt2, can produce diabetes, knockout of the p85 subunit of PI(3)K, IRS-1 or GLUT4 does not (summarized in Table 1 ). Conversely, knockout of single genes that are involved in turning off the insulin signal, such as PTP1B and SHIP2, ameliorate diabetes in obese rodents 23, 45 . Combinatorial knockouts have been produced that mimic polygenic type 2 diabetes with heterozygous deletion of the insulin receptor and IRS-1 (ref. 76) , of the insulin receptor, IRS-1 and IRS-2 (ref. 13) , and of IRS-1 and glucokinase 77 . In some of these combina- 
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Increased insulin sensitivity 45 tions there has been clear evidence of genetic epistasis. For example, although heterozygous knockout of either the insulin receptor or IRS-1 alone does not produce diabetes, the double-heterozygous knockout produces diabetes in up to 50% of mice. This striking finding gives insight into human type 2 diabetes, where insulininduced downregulation or genetic polymorphisms in the receptor or IRS-1 alone might produce only modest changes in signalling capacity, but when combined can lead to diabetes. One genetic model that produced a surprising phenotype regarding glucose homeostasis emerged from the knockout of the p85Ȋ regulatory subunits of PI(3)K. Although, PI(3)K is central to the metabolic actions of insulin, p85Ȋ heterozygous knockout mice counter-intuitively exhibit improved insulin sensitivity 30, 31 . Furthermore, superimposition of p85Ȋ heterozygosity on the insulin receptor/IRS-1 double-heterozygous knockout protects against diabetes (Mauvais et al., personal communication). This surprising protection seems to be due to a unique feature of the insulin-signalling pathway in which the stoichiometric balance between p85Ȋ, the catalytic subunit p110 and IRS proteins is critical for optimal signal transduction.
The role of specific tissues in the pathogenesis of diabetes has been explored using the Cre-lox DNA-recombination technology to create tissue-specific knockouts of the insulin receptor 2, 62, 78, 79 and GLUT4 (refs 3,80; see Table 2 ). Despite the absence of diabetes in mice with a global knockout of GLUT4 (ref. 81) , tissue-specific knockouts of GLUT4 in muscle 80 and fat 3 have resulted in severely impaired glucose tolerance. Tissue-specific knockout of the insulin receptor has also produced often surprising results. As noted above, despite recognition that insulin stimulates glucose uptake primarily in muscle, mice with a knockout of the muscle insulin receptor have normal glucose tolerance 2 . This occurs, at least in part, as the result of a shift of glucose uptake into fat, with subsequent increases in adipose tissue mass, circulating free fatty acids (FFAs) and triglycerides 82 . Mice with a knockout of the fat-specific insulin receptor also have normal glucose tolerance, whereas the liver-specific insulin-receptor knockout shows both impaired glucose tolerance and decreased insulin clearance with marked hyperinsulinaemia 62 . Perhaps the most surprising results, however, have come from studies of mice with knockouts of the ȋ-cell-specific insulin receptor and neural/brain-specific insulin receptor 79 . The former exhibit a marked defect in glucose-stimulated insulin secretion similar to that observed in type 2 diabetes, whereas the latter exhibit increased food intake, mild adiposity, insulin resistance and hypertriglyceridaemia, as well as reduced fertility due to hypothalamic hypogonadism. Taken together, these findings suggest a unifying hypothesis for type 2 diabetes in which insulin resistance in classic target tissues, such as liver, muscle and fat, coupled with insulin resistance in ȋ-cell, brain and other tissues, combine to produce the pathophysiology of type 2 diabetes.
The fat cell regulates insulin sensitivity Free fatty acids
Adipose tissue has a special role in insulin resistance (Fig. 4) 4 Cross-talk between tissues in the regulation of glucose metabolism. Insulin is secreted from the ȋ-cells of the pancreas in response to elevations in plasma glucose. The hormone decreases glucose production from the liver, and increases glucose uptake, utilization and storage in fat and muscle. The fat cell is important in metabolic regulation, releasing FFAs that reduce glucose uptake in muscle, insulin secretion from the ȋ-cell, and increase glucose production from the liver. The fat cell can also secrete 'adipokines' such as leptin, adiponectin and TNF, which regulate food intake, energy expenditure and insulin sensitivity.
insulin resistance of diabetes and obesity by inhibiting glucose uptake, glycogen synthesis and glucose oxidation, and by increasing hepatic glucose output 63 . Elevated FFAs are also associated with a reduction in insulin-stimulated IRS-1 phosphorylation and IRS-1-associated PI(3)K activity 83 . The link between increased circulating FFAs and insulin resistance might involve accumulation of triglycerides and fatty acid-derived metabolites (diacylglycerol, fatty acyl-CoA and ceramides) in muscle and liver. Nuclear magnetic resonance spectroscopy has shown a close correlation between intramyocellular triglyceride content and whole-body insulin resistance in patients with obesity and type 2 diabetes 84 . Transgenic mice with muscle-or liver-specific overexpression of lipoprotein lipase exhibit increases in tissue triglyceride content that correlate with decreases in insulin action and activation of IRS-associated PI(3)K 85 . Activation of PKC and/or IȔB kinase and serine phosphorylation of the insulin receptor and its substrates might be important 83 .
Adipokines
In addition to its role as a storage depot for lipid, the fat cell produces and secretes a number of hormones, collectively called adipokines, which may profoundly influence metabolism and energy expenditure. Expression of tumour-necrosis factor-Ȋ (TNF-Ȋ) is increased in fat of obese rodents and humans, and has been shown to produce serine phosphorylation of IRS-1, resulting in reduced insulin receptor kinase activity and insulin resistance 19 . In rodents, anti-TNF-Ȋ reagents significantly improved insulin resistance 86 , although in humans the importance of this mechanism is much debated, as limited studies of anti-TNF reagents have shown little or no effect on the insulin-resistant state 87 .
Leptin is a member of the cytokine family of hormones that is produced by adipose tissue and acts on receptors in the central nervous system and other sites to inhibit food intake and promote energy expenditure. Insulin resistance characterizes states of severe leptin deficiency or resistance, such as ob/ob or db/db mice, or genetic models of lipoatrophic diabetes. In some of these, administration of exogenous leptin improves glucose tolerance and insulin sensitivity independently of effects on food intake, probably by affecting neuroendocrine pathways that modulate insulin action in the liver 88, 89 , although this cytokine might also have direct effects on hepatic cells 90 . Adiponectin (also called Acrp30 or adipoQ) is a fat cell-derived peptide possessing a collagenous domain at the amino terminus and a globular domain that shares homology with complement factor C1q 91 . Recent studies have shown that expression of adiponectin mRNA is decreased in obese humans and mice and some models of lipoatrophic diabetes. Acute treatment of mice with this adipokine decreases insulin resistance, decreases plasma FFAs and the triglyceride content of muscle and liver, and increases expression of genes involved in fatty-acid oxidation and energy expenditure 92 . In lipoatrophic mice, insulin resistance is reversed by the combination of physiological doses of adiponectin and leptin, but only partially by either adiponectin or leptin alone. In isolated hepatocytes, adiponectin increased the ability of insulin to suppress glucose production 93 . A recent genome-wide scan in humans also mapped a susceptibility locus for type 2 diabetes and metabolic syndrome to chromosome 3q27 in a region near the adiponectin gene 94 . Resistin is the most recently discovered peptide hormone to be secreted by adipocytes. Resistin belongs to a family of related secreted proteins termed RELMs (resistin-like molecules) and FIZZ (found in inflammatory zone) 95 . Initial studies suggested that resistin might cause insulin resistance, as levels were increased in obese mice and reduced by antidiabetic drugs of the thiazolidinedione class. Furthermore, administration of antiresistin antibody seemed to improve blood sugar and insulin action in mice with diet-induced obesity. But subsequent studies have not confirmed these initial findings 96 . The potential role of resistin is further complicated by uncertainty about existence of a human homologue of the hormone.
Perspectives
There has been considerable progress over the past few years in unravelling the mechanisms of insulin action, and the molecular defects that give rise to insulin resistance. Recent advances dissecting the signalling pathways, cellular architecture and spatial compartmentalization of proteins, coupled with the sophisticated genetic analysis of the system, have yielded quantum leaps in our insight into how proteins and tissues interact to control glucose and lipid metabolism. But many gaps remain in our understanding of these processes, and in the pathophysiology underling insulin resistance. We need to define the missing steps in the insulin-signalling network, elucidate the mechanisms of cross-talk in the system, and determine the genetic susceptibility of insulin resistance and the interactions between genes and environment. Such studies will provide new insights into diabetes and insulin resistance, perhaps even allowing a more focused and individualized approach to therapy or prevention of these disorders.
s s
